Yearly Archives: 2017

Ortho Clinical Diagnostics and sphingotec Announce Strategic Agreement Regarding Novel Biomarker for Decreasing Re-hospitalizations in Heart Failure

sphingotest® bio-ADM® Assay can help reduce re-admissions and death by measuring residual congestion. Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, and SphingoTec GmbH today announced a long-term, global strategic agreement regarding the endothelial function marker, biologically active Adrenomedullin (sphingotest® bio-ADM®), which measures patients’ rate of recovery from acute heart failure, providing…
Read more

Review paper on Proenkephalin as a Novel Biomarker for Kidney Function

-scientific paper shows proenkephalin as the new biomarker for the assessment of kidney function as a more accurate marker to timely detect impaired kidney function when compared with conventional methods- HENNIGSDORF, Germany — SphingoTec GmbH announces in the early release of September 2017 issue of the Journal of Applied Laboratory Medicine the first review about proenkephalin[1]…
Read more

sphingotec and Shuwen Biotech partner to market sphingotec´s biomarkers portfolio in China

German diagnostic company SphingoTec GmbH (Hennigsdorf) and Chinese Company Shuwen Biotech Co. Ltd (Deqing) have signed an agreement to market Sphingotec’s biomarkers portfolio in China. Under the agreement, Shuwen will directly develop and market Sphingotec reliable immunoassays. For acute care, these are the Sphingotest® penKid and Sphingotest® bio-ADM tests, set to improve therapy monitoring and…
Read more